Australia has become the first country to allow authorized psychiatrists to prescribe MDMA for PTSD and psilocybin for treatment-resistant depression.
Breathe Life Sciences, a company previously focused on medicinal cannabis, obtained a license to manufacture both substances and now supplies clinics across the country.
Regulation and Manufacturing
- Regulation change: In 2023, Australia amended laws to permit the medical use of MDMA and psilocybin under strict conditions.
- Manufacturing: Breathe Life Sciences processes MDMA and psilocybin at a secure facility in Brisbane. The drugs are stored in a separate, restricted-access vault and undergo multiple tests for purity and contaminants.
Scale and Cost
- Scale: The company produces over 3 million products annually for more than 300 clients. MDMA and psilocybin account for only 1–2% of sales.
- Prescriptions: As of the report, 40 psychiatrists hold approvals for both substances outside clinical trials. Approximately 164 patients have received MDMA therapy and 74 patients psilocybin therapy.
- Cost: At the Empax Centre in Perth, MDMA therapy costs about $30,000 and psilocybin therapy about $20,000. Medibank Private became the first health insurer to fund such psychotherapy.
- Veterans: The Department of Veterans' Affairs provides access to psychedelic-assisted therapy for veterans with severe PTSD or treatment-resistant depression.
Therapeutic Context
- Mechanism: According to trauma therapist Danielle Desforges, MDMA reduces activity in the amygdala, which is involved in the fight-or-flight response, allowing patients to process traumatic memories more easily.
- Patient experience: Jess Yugovich, who underwent MDMA-assisted therapy after losing her daughter, reported that the treatment allowed her to revisit and process trauma without being overwhelmed by emotions. She emphasized that therapy is as important as the drug.
- Expert views: Psychiatrist Jon Laugharne noted that the treatments open up brain networks, enabling patients to gain new perspectives. Professor Adam Guastella from the University of Sydney cautioned that the treatments are not suitable for everyone and must occur under medical supervision due to potential side effects (e.g., nausea, cardiac issues in predisposed individuals).
Safety and Regulation
- Testing: All raw materials and finished products are tested for heavy metals, pesticides, bacteria, and chemical consistency.
- Access restrictions: Only select staff can work with MDMA and psilocybin.
- Risk reduction: Experts stress that legal, regulated use differs significantly from illegal street use, which carries higher risks due to unknown doses and contaminants.
Market Outlook
- Investment perspective: Scott Phillips of The Motley Fool described the market as uncertain, noting that while the potential is large, the therapy may remain niche. He cautioned that investor expectations may not be met.
- Early stage: Mental health experts consider the clinical results promising but emphasize the need for ongoing monitoring of adverse effects.
"The therapy is as important as the drug." — Jess Yugovich, patient
Key Statistics
- Patients treated outside trials: MDMA therapy: ~164; psilocybin therapy: ~74
- Approved psychiatrists: 40
- Empax Centre patients since October 2023: Over 80 for MDMA; about 10 for psilocybin